NEMO: Nociception and BIS Level Monitoring in COVID-19 Patients in the Intensive Care Unit

Sponsor
Leiden University Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT05579106
Collaborator
(none)
40
1
30
40.6

Study Details

Study Description

Brief Summary

Pain (nociception), stress and discomfort are difficult to detect in sedated and intubated patients during mechanical ventilation. In order to improve this several nociception level monitors (NOL) were developed that objectively track nociception in sedated or anesthetized patients. Earlier studies showed that for sedated and intubated patients in the operating room, using such monitors is beneficial in reducing stress hormones and post operative pain scores. In this study the investigators aim to observe whether the NOL could be equally beneficial in managing nociception in sedated and intubated ICU patients.

Condition or Disease Intervention/Treatment Phase
  • Device: Nociception Level Monitor (NOL) by Medasense Biometrics Ltd., Israel
  • Device: Bispectral index (BIS)
  • Other: Questionnaire perception of the nurse on pain patient

Detailed Description

To date it remains challenging to adequately titrate analgesic medication in sedated and anesthetized patients. Recently, nociception monitoring was introduced to guide analgesic treatment in sedated and anesthetized surgical patients. One such monitor is the Nociception Level (NOL; Medasense Biometrics Ltd., Israel). The NOL combines various measurements such as, skin conductance, heart rate, heart rate variability and photoplethysmograph amplitude, and translates these inputs into a single index ranging from 0 (no nociception) to 100 (maximal nociception). Earlier studies have shown that during surgery, the NOL-guided opioid treatment resulted in improved hemodynamics and reduced postoperative pain.

In the COVID-19 pandemic, patients admitted in the Intensive Care Unit (ICU), needed excessive amounts of sedatives, analgesics and muscle relaxants during mechanical ventilation. To determine its value in the ICU, the investigators measured NOL values in COVID and non-COVID ICU patients in an earlier study. The aim of the investigators was to verify the assumption that COVID-19 patients were overdosed on opioids. Since the investigators indeed did observe lower NOL values in COVID-19 patients than in non-COVID patients in an earlier study, the investigators expanded the study to determine whether sedatives were equally overdosed, by also measuring the bispectral index (BIS). With this extra information the investigators also hope to determine whether it is feasible to use the NOL in the ICU.

Study Design

Study Type:
Observational
Anticipated Enrollment :
40 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Nociception and BIS Level Monitoring in COVID-19 Patients in the Intensive Care Unit
Actual Study Start Date :
Nov 8, 2022
Anticipated Primary Completion Date :
Dec 8, 2022
Anticipated Study Completion Date :
Dec 8, 2022

Arms and Interventions

Arm Intervention/Treatment
Covid-19 patients

Mechanically ventilated and sedated adult patients with proven COVID-19 infection by PCR of nose- or airway sample. The nociception of this patient will be monitored by the nociception level monitor for 8 hours.

Device: Nociception Level Monitor (NOL) by Medasense Biometrics Ltd., Israel
The NOL monitor measures various parameters via a sensor in a finger probe that is attached to the patient. These parameters are: Temperature Galvanic skin response Accelerometer Photoplethysmograph (pulse rate, pulse rate variability, photoplethysmograph amplitude) All this data is combined in an algorithm which produces a number between 0-100. Between 10-25 indicates adequate analgesia, below 10 too much analgesia, above 25 too little analgesia. No actions are taken based on this measurement.

Device: Bispectral index (BIS)
The BIS processes EEG information to provide a direct measurement of the patient's level of consciousness and insight into the effects of anesthesia on the brain.

Other: Questionnaire perception of the nurse on pain patient
The investigators developed a questionnaire with 7-questions regarding the perception of the responsible nurse on the pain of the patient. When the investigators measured for 8 hours with the BIS and the NOL they will ask the nurse what his or her perception was of the pain of the patient. Eventually the investigators will compare the answers of this questionnaire with the NOL and BIS values that they observed, whether the information corresponds or not.

non-COVID-19 patients

Mechanically ventilated and sedated adult patients not infected with COVID-19 infection. The nociception of this patient will be monitored by the nociception level monitor for 8 hours.

Device: Nociception Level Monitor (NOL) by Medasense Biometrics Ltd., Israel
The NOL monitor measures various parameters via a sensor in a finger probe that is attached to the patient. These parameters are: Temperature Galvanic skin response Accelerometer Photoplethysmograph (pulse rate, pulse rate variability, photoplethysmograph amplitude) All this data is combined in an algorithm which produces a number between 0-100. Between 10-25 indicates adequate analgesia, below 10 too much analgesia, above 25 too little analgesia. No actions are taken based on this measurement.

Device: Bispectral index (BIS)
The BIS processes EEG information to provide a direct measurement of the patient's level of consciousness and insight into the effects of anesthesia on the brain.

Other: Questionnaire perception of the nurse on pain patient
The investigators developed a questionnaire with 7-questions regarding the perception of the responsible nurse on the pain of the patient. When the investigators measured for 8 hours with the BIS and the NOL they will ask the nurse what his or her perception was of the pain of the patient. Eventually the investigators will compare the answers of this questionnaire with the NOL and BIS values that they observed, whether the information corresponds or not.

Outcome Measures

Primary Outcome Measures

  1. BIS and NOL values over time [8 hours]

    The observation of the BIS and NOL values over time

Secondary Outcome Measures

  1. Propofol and opioid dosage [8 hours]

    Propofol and opioid dosage will be monitored during 8 hours

  2. Feasibility of using the NOL in the ICU [8 hours]

    Is it possible to use the NOL on ICU patients and does it monitor correctly

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • aged 18 years or older

  • mechanical ventilation for any reason

  • deemed suitable by the investigators

Exclusion Criteria:
  • aged 17 years or younger

  • severe peripheral edema

  • veno-arterial (VA) and veno-venous (VV) exctracorporeal membrane oxygenation (ECMO)

  • heart rate below 35

  • abdominal position

  • not deemed suitable by the investigators

Contacts and Locations

Locations

Site City State Country Postal Code
1 Leiden University Medical Centre Leiden Zuid-holland Netherlands 2333ZA

Sponsors and Collaborators

  • Leiden University Medical Center

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Albert Dahan, Professor Anesthesiology, Leiden University Medical Center
ClinicalTrials.gov Identifier:
NCT05579106
Other Study ID Numbers:
  • CoCo 2021-017
First Posted:
Oct 13, 2022
Last Update Posted:
Nov 8, 2022
Last Verified:
Nov 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 8, 2022